Cytokines as emerging targets in the treatment of heart failure

被引:49
作者
Baumgarten, G
Knuefermann, P
Mann, DL
机构
[1] VA Med Ctr, Dept Med, Winters Ctr Heart Failure Res, Cardiol Sect, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
关键词
D O I
10.1016/S1050-1738(00)00063-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent studies have identified the importance of biologically active molecules such as neurohormones in disease progression in heart failure. More recently it has become apparent that in addition to neurohormones another portfolio of biologically active molecules termed cytokines are also expressed in the setting of heart failure. This article reviews recent clinical and experimental material which suggest that the cytokines such as tumor necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6) may represent another class of biologically active molecules that are responsible for the development and progression of heart failure. In addition, we also review the early results from clinical trials that have utilized various targeted anti-cytokine strategies in patients with heart failure. (C) 2001, Elsevier Science Inc.
引用
收藏
页码:216 / 223
页数:8
相关论文
共 49 条
  • [1] Elevated soluble CD 14 receptors and altered cytokines in chronic heart failure
    Anker, SD
    Egerer, KR
    Volk, HD
    Kox, WJ
    PooleWilson, PA
    Coats, AJS
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (10) : 1426 - &
  • [2] Anker SD, 1997, CIRCULATION, V96, P526
  • [3] Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats
    Bozkurt, B
    Kribbs, SB
    Clubb, FJ
    Michael, LH
    Didenko, VV
    Hornsby, PJ
    Seta, Y
    Oral, H
    Spinale, FG
    Mann, DL
    [J]. CIRCULATION, 1998, 97 (14) : 1382 - 1391
  • [4] Bozkurt B, 1996, HEART FAIL REV, V1, P211
  • [5] Interleukin-6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure
    Deng, MC
    Erren, M
    Lutgen, A
    Zimmermann, P
    Brisse, B
    Schmitz, W
    Assmann, G
    Breithardt, G
    Scheld, HH
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 1996, 57 (02) : 129 - 134
  • [6] Safety and efficacy of a soluble P75 tumor necrosis factor receptor (enbrel, etanercept) in patients with advanced heart failure
    Deswal, A
    Bozkurt, B
    Seta, Y
    Parilti-Eiswirth, S
    Hayes, FA
    Blosch, C
    Mann, DL
    [J]. CIRCULATION, 1999, 99 (25) : 3224 - 3226
  • [7] Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: Implications for clinical trials
    Dibbs, Z
    Thornby, J
    White, BG
    Mann, DL
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (07) : 1935 - 1942
  • [8] DUTKA DP, 1993, BRIT HEART J, V70, P141
  • [9] TUMOR-NECROSIS-FACTOR SOLUBLE RECEPTORS IN PATIENTS WITH VARIOUS DEGREES OF CONGESTIVE-HEART-FAILURE
    FERRARI, R
    BACHETTI, T
    CONFORTINI, R
    OPASICH, C
    FEBO, O
    CORTI, A
    CASSANI, G
    VISIOLI, O
    [J]. CIRCULATION, 1995, 92 (06) : 1479 - 1486
  • [10] THE TISSUE DISTRIBUTION OF TUMOR-NECROSIS-FACTOR BIOSYNTHESIS DURING ENDOTOXEMIA
    GIROIR, BP
    JOHNSON, JH
    BROWN, T
    ALLEN, GL
    BEUTLER, B
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (03) : 693 - 698